The ability of FST to prevent metastatic progression, combined with the propensity for FST to bind and inhibit activin signaling, suggests that activin secreted from the microenvironment may be a key driver of metastatic progression in breast cancer, similarly to TGF-β. Here, TGFB1 is linked to breast carcinoma.